
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
How can we, as clinicians, understand how trauma has affected our patients and respond in the most effective way?
Larry Culpepper, MD, MPH, discusses how clinicians can most effectively understand and address the effects of trauma on patients at the
Dr Culpepper is professor of family medicine at Boston University School of Medicine.




